Adjuvant TRastuzumab Deruxtecan Plus Fluoropyrimidine Versus Standard Chemotherapy in HER2-positive Gastric or Gastroesophageal Cancer Patients with Persistence of Minimal Residual Disease in Liquid Biopsy after Pre-Operative Chemotherapy and Radical Surgery: the Multicentre, Phase II Randomized TRINITY Trial